nach oben

Erschienen in:

01.08.2015 | Research Article

Association of TP53 gene polymorphisms with susceptibility of bladder cancer in Bangladeshi population

verfasst von: Md. Bayejid Hosen, Md. Abdus Salam, Md. Fakhrul Islam, Ashfaque Hossain, M Zakir Hossain Hawlader, Yearul Kabir

Erschienen in: Tumor Biology | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

TP53 is considered to be the most frequently mutated gene in every forms of human cancer. The objective of this study was to evaluate the association of TP53 codon 72 and 248 polymorphisms with the susceptibility and severity of bladder cancer in Bangladeshi population. A case-control study on 102 bladder cancer patients and 140 control subjects was conducted. The genotype analysis was done by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) method. The patients with Pro/Pro genotypes at 72 position were at high risk (odds ratio (OR) = 3.02; 95 % confidence interval (95 % CI) = 1.42 to 6.40) of developing bladder cancer. The cigarette smokers with Pro/Pro genotypes at 72 position were found to have a 3.91-fold increased risk to develop bladder cancer (OR = 3.91; 95 % CI = 1.33 to 11.5). There was no significant association of codon 248 polymorphisms with bladder cancer in the study population. Taken together, these findings indicate an association between p53 codon72 polymorphism and bladder cancer risk in Bangladeshi population.

Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer. 2002;2:331–41.CrossRefPubMed

Anand P, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008;25:2097–116.CrossRefPubMedPubMedCentral

Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, et al. The diploid genome sequence of an individual human. PLoS Biol. 2007;5:e254. doi:10.1371/journal.pbio.0050254.CrossRefPubMedPubMedCentral

Shastry B. SNP alleles in human disease and evolution. J Hum Genet. 2002;47:561–6.CrossRefPubMed

Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences and clinical use. Cold Spring Harbor Prospect Biol. 2010;2(1):a001008. doi:10.1101/cshperspect.a001008.

Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R, et al. Mutations and polymorphisms in tp53 gene—an overview on the role in colorectal cancer. Mutagenesis. 2012;27:211–8.CrossRefPubMed

Duffy MJ, Synnott NC, McGowan PM, Crown J, O’Connor D, Gallagher WM. p53 as a target for the treatment of cancer. Cancer Treat Rev. 2014;40:1153–60.CrossRefPubMed

Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95–107.CrossRefPubMed

Anastasiadis A, Reijke TME. Best practice in the treatment of non-muscle invasive bladder cancer. Ther Adv Urol. 2012;4:13–32.CrossRefPubMedPubMedCentral

10.

Xu T, Xu ZC, Zou Q, Yu B, Huang XE. P53 Arg72Pro polymorphism and bladder cancer risk—meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev. 2011;13:2349–54.CrossRef

11.

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed

12.

Franekova M, Halasova E, Bukovska E, Luptak J, Dobrota D. Gene polymorphisms in bladder cancer. Urol Oncol. 2008;l26:1–8.CrossRef

13.

Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A, Saïd S, et al. No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci. 2003;1010:764–70.CrossRefPubMed

14.

Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 2002;179:175–83.CrossRefPubMed

15.

Furihata M, Kurabayashl A, Matsumoto M, Sonobe H, Ohtsuki Y, Terao N, et al. Frequent phosphorylation at serine 392 in overexpressed p53 protein due to missense mutation in carcinoma of the urinary tract. J Pathol. 2002;197:82–8.CrossRefPubMed

16.

Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol. 2003;169:1219–28.CrossRefPubMed

17.

Van-Oijen MGCT, Slootweg PJ. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res. 2000;6:2138–45.PubMed

18.

Jaiswal PK, Apul G, Mittal RD. Association of p53 codon 248 (exon 7) with urinary bladder cancer risk in the North Indian population. Biosci Trends. 2011;5:205–10.CrossRefPubMed

19.

Inatomi H, Katoh T, Kawamoto T, Matsumoto T. NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese. Int J Urol. 1999;6:446–54.CrossRefPubMed

20.

World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013. http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed 17 Oct 2014

21.

Hosen MB, Islam J, Salam MA, Islam MF, Hawlader MZH, Kabir Y. N-acetyltransferase 2 gene polymorphism as a biomarker for susceptibility to bladder cancer in Bangladeshi population. Asia-Pac J Clin Oncol. 2014. doi:10.111/ajco.12291.PubMed

22.

Islam MS, Ahmed MU, Sayeed MSB, Maruf AA, Mostofa AGM, Hussain SMA, et al. Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. Clin Chim Acta. 2013;416:11–9.CrossRefPubMed

23.

Hsieh YY, Lin CS. p53 codon 11, 72 and 248 gene polymorphisms in endometriosis. Int J Biol Sci. 2006;2:188–93.CrossRefPubMedPubMedCentral

24.

Zhang R, Chen W, Zhang W, Jiang Q, Liu C, Lin Y, et al. Genetic polymorphisms of p53 codon 72 and bladder cancer susceptibility: a hospital-based case–control study. Genet Test Mol Biomarkers. 2011;15:337–41.CrossRefPubMed

25.

Xu T, Xu ZC, Zou Q, Yu B, Huang XE. P53 Arg72Pro polymorphism and bladder cancer risk—meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev. 2012;13:2349–54.CrossRefPubMed

26.

Lin HY, Huang CH, Yu TJ, Wu WJ, Yang MC, Lung FW. p53 codon 72 polymorphism as a progression index for bladder cancer. Oncol Rep. 2012;27:1193–9.PubMed

27.

Siddique M, Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 2006;25:3489–500.CrossRefPubMed

28.

Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10:311–22.CrossRefPubMed

29.

Zeegers MP, Kellen E, Buntinx F, van den Brandt PA. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol. 2004;21:392–401.CrossRefPubMed

30.

Probst-Hensch NM, Bell DA, Watson MA, Skipper PL, Tannenbaum SR, Chan KK, et al. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol Biomarkers Prev. 2000;9:619–23.PubMed

31.

Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J Clin Invest. 2008;118:1590–605.CrossRefPubMedPubMedCentral

32.

Rahim NG, Harismendy O, Topol EJ, Frazer KA. Genetic determinants of phenotypic diversity in humans. Genome Biol. 2008;9:215. doi:10.1186/gb-2008-9-4-215.CrossRefPubMedPubMedCentral

33.

Dumont P, Leu JI, Della Pietra 3rd AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–65.CrossRefPubMed

34.

Zhu F, Dolle ME, Berton TR, Kuiper RV, Capps C, Espejo A, et al. Mouse models for the p53 R72P polymorphism mimic human phenotypes. Cancer Res. 2010;70:5851–9.CrossRefPubMedPubMedCentral

35.

Frank AK, Leu JI, Zhou Y, Devarajan K, Nedelko T, Klein-Szanto A, et al. The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}b and transactivation of genes involved in immunity and inflammation. Mol Cell Biol. 2011;31:1201–13.CrossRefPubMedPubMedCentral

Titel: Association of TP53 gene polymorphisms with susceptibility of bladder cancer in Bangladeshi population
verfasst von: Md. Bayejid Hosen
Md. Abdus Salam
Md. Fakhrul Islam
Ashfaque Hossain
M Zakir Hossain Hawlader
Yearul Kabir
Publikationsdatum: 01.08.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 8/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3324-3

Springer Medizin

Association of TP53 gene polymorphisms with susceptibility of bladder cancer in Bangladeshi population

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2015

Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells

CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients

Platelet VEGF and serum TGF-β1 levels predict chemotherapy response in non-small cell lung cancer patients

Identification of suitable endogenous controls for gene and miRNA expression studies in irradiated prostate cancer cells

Thermo-chemotherapy Induced miR-218 upregulation inhibits the invasion of gastric cancer via targeting Gli2 and E-cadherin

NFKB1/NFKBIa polymorphisms are associated with the progression of cervical carcinoma in HPV-infected postmenopausal women from rural area

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie